Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-15T01:35:22.830Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of species and subgenotypes of bovine viral diarrhea virus on control by vaccination

Published online by Cambridge University Press:  08 June 2015

Robert W. Fulton
Robert W. Fulton*
Affiliation:
Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA
*
Corresponding author. E-mail: Robert.fulton@okstate.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Bovine viral diarrhea viruses (BVDV) are diverse genetically and antigenically. This diversity impacts both diagnostic testing and vaccination. In North America, there are two BVDV species, 1 and 2 with 3 subgentoypes, BVDV1a, BVDV1b and BVDV2a. Initially, US vaccines contained BVDV1a cytopathic strains. With the reporting of BVDV2 severe disease in Canada and the USA there was focus on protection by BVDV1a vaccines on BVDV2 disease. There was also emphasis of controlling persistently infected (PI) cattle resulted in studies for fetal protection afforded by BVDV1a vaccines. Initially, studies indicated that some BVDV1a vaccines gave less than 100% protection against BVDV2 challenge for fetal infection. Eventually vaccines in North America added BVDV2a to modified live virus (MLV) and killed BVDV1a vaccines. Ideally, vaccines should stimulate complete immunity providing 100% protection against disease, viremias, shedding, and 100% fetal protection in vaccinates when challenged with a range of diverse antigenic viruses (subgenotypes). There should be a long duration of immunity stimulated by vaccines, especially for fetal protection. MLV vaccines should be safe when given according to the label and free of other pathogens. While vaccines have now included BVDV1a and BVDV2a, with the discovery of the predominate subgenotype of BVDV in the USA to be BVDV1b, approximately 75% or greater in prevalence, protection in acute challenge and fetal protection studies became more apparent for BVDV1b. Thus many published studies examined protection by BVDV1a and BVDV2a vaccines against BVDV1b in acute challenge and fetal protection studies. There are no current BVDV1b vaccines in the USA. There are now more regulations on BVDV reproductive effects by the USDA Center for Veterinary Biologics (CVB) regarding label claims for protection against abortion, PI calves, and fetal infections, including expectations for studies regarding those claims. Also, the USDA CVB has a memorandum providing the guidance for exemption of the warning label statement against the use of the MLV BVDV in pregnant cows and calves nursing pregnant cows. In reviews of published studies in the USA, the results of acute challenge and fetal protection studies are described, including subgenotypes in vaccines and challenge strains and the results in vaccinates and the vaccinates' fetuses/newborns. In general, vaccines provide protection against heterologous strains, ranging from 100% to partial but statistically significant protection. In recent studies, the duration of immunity afforded by vaccines was investigated and reported. Issues of contamination remain, especially since fetal bovine serums may be contaminated with noncytopathic BVDV. In addition, the potential for immunosuppression by MLV vaccines exists, and new vaccines will be assessed in the future to prove those MLV components are not immunosuppressive by experimental studies. As new subgenotypes are found, the efficacy of the current vaccines should be evaluated for these new strains.

Keywords

bovine viral diarrhea virusvaccinesspecies and subgenotypes
Type
Review Article
Information
Animal Health Research Reviews , Volume 16 , Issue 1 , June 2015 , pp. 40 - 54
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baker, JC (1995). The clinical manifestations of bovine viral diarrhea infection in North America. Veterinary Clinics of North America: Food Animal Practice 11: 425–445.Google Scholar
Balint, A, Baule, C, Palfi, V and Belak, S (2005). Retrospective genome analysis of a live vaccine strain of bovine viral diarrhea virus. Veterinary Research 36: 89–99.CrossRefGoogle ScholarPubMed
Barkema, HW, Bartels, CJ, van Wuijckhuise, L, Hesselink, JW, Holzhauer, M, Weber, MF, Franken, P, Kock, PA, Bruschke, C and Zimmer, GM (2001). Outbreak of bovine virus diarrhea on Dutch dairy farms induced by a bovine herpesvirus 1 marker vaccine contaminated with bovine virus diarrhea virus type 2. Tijdschr Diergeneeskd 126: 158–165.Google ScholarPubMed
Bauermann, FV, Harmon, A, Flores, EF, Falkenberg, SM, Reecy, JM and Ridpath, JF (2013a). In vitro neutralization of HoBi-like viruses by antibodies in serum of cattle immunized with inactivated or modified live vaccines of bovine viral diarrhea viruses 1 and 2. Veterinary Microbiology 166: 242–245.CrossRefGoogle ScholarPubMed
Bauermann, FV, Ridpath, JF, Weiblen, R and Flores, EF (2013b). HoBi-like viruses; an emerging group of pestiviruses. Journal of Veterinary Diagnostic Investigation 25: 6–15.CrossRefGoogle ScholarPubMed
Becher, P, Orlich, M, Shannon, AD, Horner, G, Konig, M and Thiel, HJ (1997). Phylogenetic analysis of pestiviruses from domestic and wild ruminants. Journal of General Virology 78: 1357–1366.CrossRefGoogle ScholarPubMed
Becher, P and Thiel, HJ (2002). Genus Pestivirus (Flaviviridae). In: Tidona, CA and Darai, G (eds) The Springer Index of Viruses. Heidelberg, Germany: Springer-Verlag, pp. 327–331.Google Scholar
Bolin, S, Moennig, V, Kelso Gourley, NE and Ridpath, J (1988). Monoclonal antibodies with neutralizing activity segregate isolates of bovine viral diarrhea virus into groups. Archives of Virology 99: 117–123.CrossRefGoogle ScholarPubMed
Bolin, SR and Ridpath, JF (1989). Specificity of neutralizing and precipitating antibodies induced in healthy calves by monovalent modified-live bovine viral diarrhea virus vaccines. American Journal for Veterinary Research 50: 817–821.Google ScholarPubMed
Bolin, SR and Ridpath, JR (1990). Range of viral neutralizing activity and molecular specificity of antibodies induced in cattle by inactivated bovine viral diarrhea virus vaccines. American Journal for Veterinary Research 51: 703–707.CrossRefGoogle ScholarPubMed
Bolin, SR, Matthews, PJ and Ridpath, JF (1991). Methods for detection and frequency of contamination of fetal calf serum and bovine viral diarrhea virus and antibodies against bovine viral diarrhea virus. Journal of Veterinary Diagnostic Investigation 3: 1999–2003.CrossRefGoogle ScholarPubMed
Bolin, SR and Ridpath, JF (1998). Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serums. Journal of Veterinary Diagnostic Investigation 10: 135–139.CrossRefGoogle Scholar
Brock, KV and Cortese, VS (2001). Experimental fetal challenge using type 11 bovine viral diarrhea virus in cattle vaccinated with modified-live virus vaccine. Veterinary Therapeutics 2: 354–360.Google Scholar
Brock, KV, McCarty, K, Chase, CCL and Harland, R (2006). Protection against fetal infection with either bovine viral diarrhea virus type 1 or type 2 using a noncytopathic type 1 modified-live virus vaccine. Veterinary Therapeutics 7: 27–34.Google ScholarPubMed
Brock, KV, Widel, P, Walz, P and Walz, HL (2007). Onset of protection from experimental infection with type 2 bovine viral diarrhea virus following vaccination with a modified-live vaccine. Veterinary Therapeutics 9: 88–96.Google Scholar
Bruschke, CJ, Paal, HA and Weerdmeester, K (2001). Detection of bovine virus diarrhea virus in a live bovine herpes virus 1 marker vaccine. Tijdschr Diergeneeskd 126: 189–190.Google Scholar
Carman, S, van Dreumel, T, Ridpath, J, Hazlett, M, Alves, D, Dubovi, E, Tremblay, R, Bolin, S, Godkin, A and Andersen, N (1998). Severe acute bovine viral diarrhea in Ontario, 1993–1995. Journal of Veterinary Disease Investigation 10: 27–35.CrossRefGoogle ScholarPubMed
Compendium of Veterinary Products. (2010). North American Compendiums. 12th edn.Port Huron, MI, pp. 1–1848.Google Scholar
Cortese, VS, Grooms, DL, Ellis, J, Bolin, SR, Ridpath, JF and Brock, KV (1998a). Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of modified-live virus vaccine. American Journal for Veterinary Research 59: 1409–1413.CrossRefGoogle ScholarPubMed
Cortese, VS, West, KH, Hassard, LE, Carman, S and Ellis, JA (1998b). Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type-11 isolate of bovine viral diarrhea virus. Journal of American Veterinary Medical Association 213: 1312–1319.CrossRefGoogle Scholar
Dean, HJ and Leyh, R (1999). Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine 12: 1117–1124.CrossRefGoogle Scholar
Dean, HJ, Hunsaker, BD, Bailey, OD and Wasmoen, T (2003). Prevention of persistent infection in calves by vaccination of dams with noncytopathic type-1 modified-live bovine viral diarrhea virus prior to breeding. American Journal for Veterinary Research 64: 530–537.CrossRefGoogle ScholarPubMed
Ellsworth, MA, Fairbanks, KK, Behan, S, Jackson, JA, Goodyear, M, Olen, NL, Meinert, TR and Leyh, RD (2006). Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of dams. Veterinary Therapeutics 7: 295–304.Google ScholarPubMed
Fairbanks, K, Schnackel, J and Chase, CCL (2003). Evaluation of modified live virus type-1a bovine viral diarrhea virus vaccine (Singer strain) against a type-2 (strain 890) challenge. Veterinary Therapeutics 4: 24–34.Google ScholarPubMed
Fairbanks, KK, Rinehart, CL, Ohnesorge, WC, Loughin, MM and Chase, CCL (2004). Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. Journal for American Veterinary Medical Association 225: 1894–1904.CrossRefGoogle ScholarPubMed
Falcone, E, Cordioli, P, Tarantino, M, Muscillo, M, Sala, G, La Rosa, G, Archetti, IL, Marianelli, C, Lombard, G and Tollis, M (2003). Experimental infection of calves with bovine viral diarrhoea virus type-2 (BVDV-2) isolated from a contaminated vaccine. Veterinary Research Communications 27: 577–589.Google Scholar
Ficken, MD, Ellsworth, MA and Tucker, CM (2006a). Evaluation of the efficacy of a modified- live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration of immunity fetal protection study. Veterinary Therapeutics 7: 283–291.Google Scholar
Ficken, MD, Ellsworth, MA, Tucker, CM and Cortese, VS (2006b). Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation. Journal of American Veterinary Medical Association 338: 1559–1564.CrossRefGoogle Scholar
Flores, EF, Ridpath, JF, Weiblen, R, Vogel, FS and Gil, LH (2002). Phylogenetic analysis of Brazilian bovine viral diarrhea virus type 2 (BVDV-2) isolates: evidence for a subgenotype within BVDV-2. Virus Research 87: 51–60.CrossRefGoogle ScholarPubMed
Fulton, RW, Confer, AW, Burge, LJ, Perino, LJ, d'Offay, JM, Payton, ME and Mock, RE (1995). Antibody responses by cattle after vaccination with commercial viral vaccines containing bovine herpesvirus-1, bovine viral diarrhea virus, parainfluenza -3 virus, and bovine respiratory syncytial virus immunogens and subsequent revaccination at day 140. Vaccine 13: 725–733.CrossRefGoogle ScholarPubMed
Fulton, RW, Burge, LJ, d'Offay, JM and Payton, ME (1997a). Serum antibody response in calves receiving modified live and/or inactivated vaccines containing bovine herpesvirus 1, bovine viral diarrhea virus, parainfluenza-3 virus and bovine respiratory syncytial virus. Bovine Practitioner 31: 90–96.CrossRefGoogle Scholar
Fulton, RW, Saliki, JT, Burge, LJ, d'Offay, JM, Bolin, SR, Maes, RK, Baker, JC and Frey, ML (1997b). Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay. Clinical and Diagnostic Laboratory Immunology 4: 380–383.CrossRefGoogle ScholarPubMed
Fulton, RW and Burge, LJ (2000). Bovine viral diarrhea virus type 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine 19: 264–274.CrossRefGoogle ScholarPubMed
Fulton, RW, Cook, BJ, Step, DL, Confer, AW, Saliki, JT, Burge, LJ, Welsh, RD, Blood, KS and Payton, M (2002a). Evaluation of animal health status of calves and their impact on feedlot performance: assessment of a retained ownership program of postweaning calves. Canadian Journal of Veterinary Research 66: 173–180.Google ScholarPubMed
Fulton, RW, Ridpath, JF, Confer, AW, Saliki, JT, Burge, LJ and Payton, ME (2003a). Bovine viral diarrhoea virus antigenic diversity: impact on disease and vaccination programmes. Biologicals 31: 89–95.CrossRefGoogle ScholarPubMed
Fulton, RW, Saliki, JT, Burge, LJ and Payton, ME (2003b). Humoral immune response and assessment of vaccine virus shedding in calves receiving modified live virus vaccines containing bovine herpesvirus-1 and bovine viral diarrhoea virus 1a. Journal of Veterinary Medicine 50: 31–37.CrossRefGoogle ScholarPubMed
Fulton, RW, Step, DL, Ridpath, JF, Saliki, JT, Confer, AW, Johnson, BJ, Briggs, RE, Hawley, RV, Burge, LJ and Payton, ME (2003c). Response of calves persistently infected with noncytopathic bovine viral diarrhea virus (BVDV) subtype 1b after vaccination with heterologous BVDV strains in modified live virus vaccines and Mannheimia haemolytica bacterin-toxoid. Vaccine 21: 2980–2985.Google Scholar
Fulton, RW, Briggs, RE, Ridpath, JF, Saliki, JT, Confer, AW, Payton, ME, Duff, GC, Step, DL and Walker, D (2005a). Transmission of bovine viral diarrhea virus 1b to susceptible and vaccinated calves by exposure to persistently infected calves. Canadian Journal for Veterinary Research 69: 161–169.Google Scholar
Fulton, RW, Ridpath, JF, Ore, S, Confer, AW, Saliki, JT, Burge, LJ and Payton, ME (2005b). Bovine viral diarrhoea virus (BVDV) subgenotypes in diagnostic laboratory accessions: distribution of BVDV1a, 1b, and 2a subgenotypes. Veterinary Microbiology 111: 35–40.CrossRefGoogle ScholarPubMed
Fulton, RW, Hessman, B, Johnson, BJ, Ridpath, JF, Saliki, J, Burge, LJ, Sjeklocha, D, Confer, AW, Funk, R and Payton, ME (2006a). Evaluation of diagnostic tests used for detection of bovine viral diarrhea virus and prevalence of BVDV Subtypes 1a, 1b, and 2a. in persistently infected cattle entering a feedlot. Journal of American Veterinary Medical Association 228: 578–584.CrossRefGoogle ScholarPubMed
Fulton, RW, Johnson, BJ, Briggs, RE, Ridpath, JF, Saliki, JT, Confer, AW, Burge, LJ, Step, DL, Walker, DA and Payton, ME (2006b). Challenge with bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in acutely infected calves. Canadian Journal for Veterinary Research 70: 121–127.Google Scholar
Fulton, RW, Blood, KS, Panciera, RJ, Payton, ME, Ridpath, JF, Confer, AW, Saliki, JT, Burge, LJ, Welsh, RD, Johnson, BJ and Reck, A (2009a). Lung pathology and infectious agents in fatal feedlot pneumonia and relationship with mortality, disease onset, and treatments. Journal of Veterinary Disease Investigation 21: 464–477.CrossRefGoogle ScholarPubMed
Fulton, RW, Hessman, BE, Ridpath, JF, Johnson, BJ, Burge, LJ, Kapil, S, Braziel, B, Kautz, K and Reck, A (2009b). Multiple diagnostic tests to identify cattle with bovine viral diarrhea virus and duration of positive tests in persistently infected cattle. Canadian Journal for Veterinary Research 73: 117–124.Google ScholarPubMed
Fulton, RW, Cook, BJ, Blood, KS, Confer, AW, Payton, ME, Step, DL, Saliki, JT, Burge, LJ and Welsh, RD (2011). Immune response to bovine respiratory disease vaccine immunogens in calves at entry to feedlot and impact on feedlot performance. Bovine Practitioner 45: 1–12.Google Scholar
Fulton, RW (2013). Host response to bovine viral diarrhea virus and interactions with infectious agents in the feedlot and breeding herd. Biologicals 41: 31–38.CrossRefGoogle ScholarPubMed
Giangaspero, M, Vacirca, G, Harasawa, R, Buttner, M, Panuccio, A, De Giuli Morghen, C, Zanetti, A, Belloli, A and Verhulst, A (2001). Genotypes of pestivirus RNA detected in live virus vaccines for human use. Journal of Veterinary Medical Sciences 63: 723–733.CrossRefGoogle ScholarPubMed
Givens, MD, Marley, SD, Jones, CA, Ensley, DT, Galik, PK, Zhang, Y, Riddell, KP, Joiner, KS, Brodersen, BW and Rodning, SP (2012). Protective effects against abortion and fetal infection following exposure to bovine viral diarrhea virus and bovine herpesvirus 1 during pregnancy in beef heifers that received two doses of a multivalent modified –live virus vaccine prior to breeding. Journal of American Veterinary Medical Association 241: 484–495.Google Scholar
Grooms, DL, Bolin, SR, Coe, PH, Borges, RJ and Coutu, CE (2007). Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle. American Journal for Veterinary Research 68: 1417–1422.CrossRefGoogle ScholarPubMed
Hessman, BE, Sjeklocha, DB, Fulton, RW, Ridpath, JF, Johnson, BJ and McElroy, DR (2012). Acute bovine viral diarrhea associated with extensive mucosal lesions, high morbidity, and mortality in a commercial feedlot. Journal of Veterinary Disease Investigation 24: 397–404.CrossRefGoogle Scholar
Kelling, CL, Hunsaker, BD, Steffen, DJ, Topliff, CL, Abdelmagid, OY and Eskridge, KM (2005). Characterization of protection from systemic infection and disease by use of a modified-live noncytopathic bovine viral diarrhea virus type 1 vaccine in experimentally infected calves. American Journal for Veterinary Research 66: 1785–1791.CrossRefGoogle ScholarPubMed
Kleiboeker, SB, Lee, SM, Jones, CA and Estes, DM (2003). Evaluation of shedding of bovine herpesvirus 1, bovine viral diarrhea virus 1, and bovine viral diarrhea virus 2 after vaccination of calves with a modified-live virus vaccine. Journal of American Veterinary Medical Association 222: 1399–1403.CrossRefGoogle ScholarPubMed
Kreeft, HA, Greiser-Wilke, I, Moennig, V and Horzinek, MC (1990). Attempts to characterize bovine viral diarrhea virus isolated from cattle after immunization with a contaminated vaccine. Dtsch Tierarztl Wochenschr 97: 63–65.Google Scholar
Leyh, RD, Fulton, RW, Stegner, JE, Goodyear, M, Witte, S, Taylor, LP, Johnson, BJ, Step, D, Ridpath, JF and Holland, BP (2011). Fetal protection in heifers vaccinated with a modified live virus vaccine containing bovine viral diarrhea virus subtypes BVDV1a and BVDV2a and exposed during gestation to cattle persistently infected with BVDV subtype 1b. American Journal for Veterinary Research 72: 367–375.CrossRefGoogle Scholar
Martin, SW, Meek, AH, Davis, DG, Thomson, RG, Johnson, JA, Lopez, A, Stephens, L, Curtis, RA, Prescott, JF, Rosendal, S, Savan, M, Zubaidy, AJ and Bolton, MR (1980). Factors associated with mortality in feedlot cattle: the Bruce County beef cattle project. Canadian Journal for Comparative Medicine 44: 1–10.Google Scholar
Martin, SW, Meek, AH, Davic, DG, Johnson, JA and Curtis, RA (1981). Factors associated with mortality in feedlot calves; the Bruce County beef cattle project, year 2. Canadian Journal for Comparative Medicine 45: 103–112.Google Scholar
Miller, MM, O'Toole, D, Cavender, JL, Cornish, TE, Dawson, TG, Smylie, JM, Fox, JH, Hill, KL, Montgomery, DL, Vasquez, M and Schumaker, BA (2013). Vaccine associated mucosal disease case study: demonstrating the importance of subsequent herd PI testing. Bovine Practitioner 47: 84–93.CrossRefGoogle Scholar
Palomares, RA, Givens, MD, Wright, JC, Walz, PH and Brock, KV (2012). Evaluation of the onset of protection induced by a modified-live virus vaccine in calves challenge inoculated with type 1b bovine viral diarrhea virus. American Journal for Veterinary Research 73: 567–574.CrossRefGoogle ScholarPubMed
Palomares, RA, Marley, SM, Givens, MD and Gallardo, RA (2013). Bovine viral diarrhea virus fetal persistent infection after immunization with a contaminated modified-live virus vaccine. Theriogenology 79: 1184–1195.CrossRefGoogle ScholarPubMed
Pellerin, C, van den Hurk, J, Lecomte, J and Tussen, P (1994). Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities. Virology 203: 260–268.CrossRefGoogle ScholarPubMed
Platt, R, Coutu, C, Meinert, T and Roth, JA (2008). Humoral and T cell-mediated immune responses to bivalent killed bovine viral diarrhea virus vaccine in beef cattle. Veterinary Immunology and Immunopathology 122: 8–15.CrossRefGoogle Scholar
Raue, R, Harmeyer, SS and Nanjiani, IA (2011). Antibody responses to inactivated vaccines and natural infection in cattle using bovine viral diarrhea virus ELISA kits: assessment of potential to differentiate infected and vaccinated animals. Veterinary Journal 187: 330–334.Google Scholar
Ridpath, JF, Bolin, SR and Dubovi, EJ (1994). Segregation of bovine viral diarrhea virus into genotypes. Virology 205: 66–74.CrossRefGoogle ScholarPubMed
Ridpath, JF and Bolin, SR (1997). Comparison of the complete genomic sequence of the border disease virus, BD31, to other pestiviruses. Virus Research 50: 237–243.CrossRefGoogle ScholarPubMed
Ridpath, JF and Bolin, SR (1998). Differentiation of types 1a, 1b, and 2 bovine viral diarrhoea virus (BVDV) by PCR. Molecular and Cellular Probes 12: 101–106.Google Scholar
Ridpath, JF, Fulton, RW, Kirkland, PD and Neil, JD (2010). Prevalence and antigenic differences observed between bovine viral diarrhea virus subgenotypes isolated from cattle in Australia and feedlots in the southwestern United States. Journal of Veterinary Diagnostic Investigation 22: 184–191.CrossRefGoogle ScholarPubMed
Ridpath, JF (2013). Immunology of BVDV vaccines. Biologicals 41: 14–19.CrossRefGoogle ScholarPubMed
Rodning, SP, Marley, MSD, Zhang, Y, Eason, AB, Nunley, CL, Walz, PH, Riddell, KP, Galik, PK, Brodersen, BW and Givens, MD (2010). Comparison of three commercial vaccines for preventing infection with bovine viral diarrhea virus. Theriogenology 73: 1154–1163.CrossRefGoogle ScholarPubMed
Roth, JA and Kaberle, ML (1983). Suppression of neutrophil and lymphocyte function induced by a vaccinal strain of bovine viral diarrhea virus with and without the administration of ACTH. American Journal for Veterinary Research 44: 2366–2372.Google Scholar
Schnackel, JA, Van Campen, H and van Olphen, A (2007). Modified-live bovine viral diarrhea virus (BVDV) type 1a vaccine provides protection against fetal infection after challenge with either type 1b or type 2 BVDV. Bovine Practitioner 41: 1–9.CrossRefGoogle Scholar
Ståhl, K, Beer, M, Schirrmeier, H, Hoffmann, B, Belák, S and Alenius, S (2010). Atypical ‘HoBi’-like pestiviruses–recent findings and implications thereof. Veterinary Microbiology 142: 90–93.Google Scholar
Stevens, ET, Brown, MS, Burdett, WW, Bolton, MW, Nordstrom, ST and Chase, CCL (2011). Efficacy of a non-adjuvanted, modified-live virus vaccine in calves with maternal antibodies against a virulent bovine viral diarrhea virus type 2a challenge seven months following vaccination. Bovine Practitioner 45: 23–31.Google Scholar
Studer, E, Bertoni, G and Candrian, U (2002). Detection and characterization of pestivirus contaminations in human live viral vaccines. Biologicals 30: 289–296.CrossRefGoogle ScholarPubMed
Van Rijn, PA, van Gennip, HG, Leendertse, CH, Brusche, CJ, Paton, DJ, Moorman, RJ and van Oirschot, JT (1997). Subdivision of the pestivirus genus based on the envelope glycoprotein E2. Virology 237: 337–348.CrossRefGoogle ScholarPubMed
Van Campen, H, Vorpal, P, Huzubazar, S, Edwards, J and Cavender, J (2000). A case report: evidence for type 2 bovine viral diarrhea virus (BVDV)-associated disease in a beef herd vaccinated with a modified-live-type 1 BVDV vaccine. Journal of Veterinary Diagnostic Investigation 12: 263–265.Google Scholar
Vilcek, S, Paton, DJ, Durkovic, B, Strojny, L, Ibata, G, Moussa, A, Loitsch, A, Rossmanith, W, Vega, S, Scicluna, MT and Paifi, V (2001). Bovine viral diarrhea virus genotype 1 can be separated into at least eleven genetic groups. Archives of Virology 146: 99–115.CrossRefGoogle ScholarPubMed
Vilcek, S, Durkovic, B, Kolesarova, M, Greiser-Wilke, I and Paton, D (2004). Genetic diversity of international bovine viral diarrhoea virus (BVDV) isolates: identification of a new BVDV-1 genetic group. Veterinary Research 35: 609–615.CrossRefGoogle ScholarPubMed
Xue, W, Mattick, D, Smith, L and Maxwell, J (2009). Fetal protection against bovine viral diarrhea virus types 1 and 2 after the use of a modified-live virus vaccine. Canadian Journal of Veterinary Research 73: 292–297.Google Scholar
Xue, W, Ellis, J, Mattick, D, Smith, L, Brady, R and Trigo, E (2010a). Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves. Vaccine 28: 3784–3792.CrossRefGoogle ScholarPubMed
Xue, W, Mattick, D, Smith, L, Umbaugh, J and Trigo, E (2010b). Vaccination with modified-live bovine viral diarrhea virus (BVDV) type 1a vaccine completely protected calves against challenge with BVDV 1 strains. Vaccine 29: 70–76.Google Scholar
Xue, W, Mattick, D and Smith, L (2011). Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus. Vaccine 29: 4657–4662.CrossRefGoogle ScholarPubMed
Zimmerman, AD, Boots, RE, Valli, JL and Chase, CCL (2006). Evaluation of protection against virulent bovine viral diarrhea virus type in calves that had maternal antibodies and were vaccinated with a modified-live vaccine. Journal of American Veterinary Medical Association 339: 1757–1761.CrossRefGoogle Scholar
Zimmerman, AD, Buterbaugh, RE, Schnackel, JA and Chase, CCL (2009). Efficacy of a modified-live virus vaccine administered to calves with maternal antibodies and challenged seven months later with a virulent bovine viral diarrhea type 2 virus. Bovine Practitioner 43: 35–43.Google Scholar
Zimmerman, AD, Klein, GL, Buterbaugh, RE, Hartman, B, Rinehart, CL and Chase, CCL (2013). Vaccination with a multivalent modified-live virus vaccine administered one prior to challenge with bovine viral diarrhea virus type 1b and 2a in pregnant heifers. Bovine Practitioner 47: 22–33.CrossRefGoogle Scholar